a case of an elderly patient on regorafenib who achieved stable disease for over 11 months with strategic dose modifications was presented .
colorectal cancer ( crc ) is one of most common cancers and leading causes of mortality in the usa , accounting for approximately 136,000 new cases and 50,000 deaths per year.1 for metastatic or unresectable crc , standard first- and second - line treatments typically involve a combination of cytotoxic chemotherapies ( eg , folfiri [ 5- fluorouracil + oxaliplatin + irinotecan])2,3 and molecular targeted agents ( eg , bevacizumab , cetuximab , panitumumab),46 which can help to improve progression - free survival and overall survival .
regorafenib , an oral multikinase inhibitor , which targets angiogenic , stromal , and oncogenic receptor tyrosine kinases , was approved by the us food and drug administration in 2012 for the treatment of patients with metastatic crc who have been previously treated with fluoropyrimidine- , oxaliplatin- , and irinotecan - based chemotherapy , an anti  vascular endothelial growth factor ( vegf ) therapy and , if kras wild - type , an anti  epidermal growth factor receptor ( egfr ) therapy.7 this approval was based on the correct study , which demonstrated a median overall survival of 6.4 months with regorafenib vs 5.0 months with placebo ( hazard ratio , 0.77 ; 95% confidence interval , 0.640.94 ; p=0.0052).8 among the most common adverse effects were fatigue , hand 